Beyond R&D: Partnership and Licensing Tactics ™
Keys to Successful Alliances with China
With wide-scale R&D restructuring to bring products to market faster and cheaper within the pharmaceutical industry, China has become the next “place to be”. Partnership and Licensing (P&L) savvy is critical to working with this increasingly dynamic Chinese market.
That’s why this year’s U.S.-CHINA PHARMA conference has been expanded to a two-day event, with Partnership and Licensing commanding a full day of its own. |
 |
So take advantage of this extended opportunity. Join the U.S.-CHINA PHARMA conference to learn about best practices and strategies in leveraging partnerships, alliances, collaborations, out-sourcing, and in-licensing to improve productivity and contain costs in R&D projects. Meet face-to-face with hundreds of leaders and visionaries who are shaping collaborations between the United States and China, and walk away with partners for your next project. |
